Back to Agenda
Adaptive Pathways and Conditional Approval – Panel Discussion
Session Chair(s)
Luca Pani, MD
Former, AIFA; Professor, Department of Psychiatry and Behavioral Sciences
University of Miami, United States
This panel will outline the possible opportunities from increasing documentation of real life and post approval data and the support provided by regulators to develop innovative drugs.
Speaker(s)
Panel Discussion
Hans-Georg Eichler, MD, MSc
Austrian Association of Social Security Bodies, Austria
Consulting Physician
Panel Discussion
Susan Forda, PhD
Eli Lilly & Company Ltd., United Kingdom
VP, GLobal Regulatory Affairs International
Panel Discussion
Niklas Hedberg, MPharm
Dental and Pharmaceutical Benefits Agency, TLV, Sweden
HTACG Co-Chair & Chief Pharmacist
Panel Discussion
François Houyez
European Organisation for Rare Diseases (EURORDIS), France
Treatment Information and Access Director, Health Policy Advisor
Panel Discussion
Tomas Salmonson, DrMed, PhD
Critical Path Institute, United States
Partner
Have an account?